Skip to main content
. Author manuscript; available in PMC: 2024 Feb 9.
Published in final edited form as: Reg Anesth Pain Med. 2019 Jan;44(1):92–99. doi: 10.1136/rapm-2018-000008

Table 3.

Baseline characteristics of the study 2 sample (n=49)

Characteristic Descriptive statistic
Sex (% female) 67.3
Race (%)
 White 61.2
 African-American 26.5
 Asian 6.1
Ethnicity (% non-Hispanic) 97.9
Age (MN±SD) 39.7±9.96
CLBP duration (median, in months) 78.7
Worst pain past 24 hours (mean±SD) 6.0±2.36
Average pain past 24 hours (mean±SD) 4.6±2.49
Best pain past 24 hours (mean±SD) 3.1±2.59
PROMIS pain interference 8a (mean±SD) 23.7±9.12
Medications (%)
 As-needed opioids 14.3
 Antidepressants 49.0
 Neuroleptics 38.7
 As-needed NSAIDs 42.9
HOME: opioid exposure (mean±SD) 2.2±1.54
HOME: euphoric response (mean±SD) 3.2±1.25

CLBP, chronic low back pain; HOME, History of Opioid Medical Exposure; NSAID, non-steroidal anti-inflammatory drug; PROMIS, Patient-Reported Outcomes Measurement Information System.